咪唑并[1,2-a]喹喔啉-2-羧酸乙酯 | 76013-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 咪唑并[1,2-a]喹喔啉-2-羧酸乙酯
• 英文名称: ethyl imidazo-[1,2-a]-quinoxaline-2-carboxylate
• 英文别名: Ethyl imidazo[1,2-a]quinoxaline-2-carboxylate
• CAS: 76013-27-9
• 化学式: C₁₃H₁₁N₃O₂
• 分子量: 241.249
• InChiKey: UMZALKINSDJRCY-UHFFFAOYSA-N

物化性质

• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  咪唑并[1,2-a]喹喔啉-2-羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 0.5h， 生成 达唑司特
  参考文献：
  名称：

  Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles

  摘要：

  4H-Imidazo[2,1-c][1,4]benzoxazine-2-carboxylic acid (3) was found to possess potent activity in the IgE-induced rat passive cutaneous anaphylaxis model which may be predictive of clinical antiallergic activity. Compared to disodium cromoglycate (DSCG, 1), 3 was less active following iv administration but unlike DSCG showed very significant oral activity. To explore the structural requirements for this activity, a range of tricyclic compounds was prepared and their activities were measured. Individual 2-carboxylic acids derived from imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles showed iv activities up to 10(3) times as potent as DSCG and many of them showed significant oral activity. From these, imidazo[1,2-a]quinoxaline-2-carboxylic acid 114 has been chosen for further development.

  DOI：

  10.1021/jm00401a009
• 作为产物：
  描述：

  1-carbethoxy-carbonylmethyl-2-amino-quinoxalinium bromide 以 乙醇 为溶剂， 反应 2.0h， 以to obtain 0.25 g of ethyl imidazo-[1,2-a]-quinoxaline-2-carboxylate as a pale yellow solid which的产率得到咪唑并[1,2-a]喹喔啉-2-羧酸乙酯
  参考文献：
  名称：

  Imidazo[2,1-C]quinolines, useful as antiallergic agents

  摘要：

  化合物的公式为##STR1##其中A选自由氮和.dbd.CH--的组合，G为##STR2##，Z选自1到5个碳原子的氢和烷基组成的组合或与Y形成碳-碳键，Z'选自氢和卤素的组合，Y为氢或与Z形成碳-碳键或与X形成.dbd.O，X为氢或与Y形成.dbd.O，R选自羟甲基、甲酰基、四唑-5-基、N-(四唑-5-基)氨基甲酰、氨甲基和氨基甲酰的组合，R.sub.1选自1到5个碳原子的卤素和烷氧基的组合，以及其无毒、药学上可接受的酸加合物，具有抗过敏活性，其制备方法。

  公开号：

  US04644002A1

文献信息

• Substituted imidazo 1,2-a-quinoxaline-4-(5H)ones, their compositions and
  申请人：Roussel Uclaf

  公开号：US04474784A1

  公开（公告）日：1984-10-02

  Novel compounds of the formula ##STR1## wherein A is selected from the group consisting of nitrogen and .dbd.CH--, G is selected from the group consisting of --0--, ##STR2## Z is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms or taken with Y forms a carbon-nitrogen or carbon-carbon bond, Z' is selected from the group consisting of hydrogen and halogen, Y is hydrogen, or taken with Z is a carbon-nitrogen or carbon-carbon bond or taken with X is .dbd.0 and X is hydrogen or taken with Y is .dbd.0, R is selected from the group consisting of hydroxymethyl, formyl, tetrazol-5-yl, N-(tetrazol-5-yl) carbamoyl, aminomethyl and carbamoyl, R.sub.1 is selected from the group consisting of hydrogen, halogen and alkoxy of 1 to 5 carbon atoms and its non-toxic, pharmaceutically acceptable acid addition salts having anti-allergic activity and their preparation.

  该文描述的是一种新型化合物，化学式为##STR1## 其中A可选自氮和.dbd.CH--，G可选自--0--，##STR2##，Z可选自氢和1至5个碳原子的烷基，或与Y形成碳氮或碳碳键，Z'可选自氢和卤素，Y为氢，或与Z形成碳氮或碳碳键，或与X形成.dbd.0，X为氢，或与Y形成.dbd.0，R可选自羟甲基、甲酰基、四唑-5-基、N-(四唑-5-基)氨基甲酰基、氨甲基和氨基甲酰基，R.sub.1可选自氢、卤素和1至5个碳原子的烷氧基，以及其无毒、药学上可接受的酸盐，具有抗过敏活性，并提供了其制备方法。
• Novel imidazoquinoxalines
  申请人：Roussel Uclaf

  公开号：US04254123A1

  公开（公告）日：1981-03-03

  Novel imidazoquinoxalines of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, --NH.sub.4, alkali metal, alkaline earth metal, magnesium, aluminum and non-toxic, pharmaceutically acceptable amines, X is selected from the group consisting of hydrogen, alkoxy of 1 to 5 carbon atoms and carbamoyl and Y and Z are individually selected from the group consisting of hydrogen and halogen and their non-toxic, pharmaceutically acceptable acid addition salts having anti-allergic activity and their preparation.

  式子为##STR1##的新型咪唑喹啉化合物，其中R选择从氢、1至5个碳原子的烷基、--NH.sub.4、碱金属、碱土金属、镁、铝和无毒、药学上可接受的胺类中选取，X选择从氢、1至5个碳原子的烷氧基和氨基甲酰中选取，Y和Z分别从氢和卤素中选取，以及它们的无毒、药学上可接受的酸盐，具有抗过敏活性，以及它们的制备方法。
• Imidazoquinoxalines and pyrroloquinoxalines
  申请人：Roussel Uclaf

  公开号：US04333934A1

  公开（公告）日：1982-06-08

  Novel compounds of the formula ##STR1## wherein A is selected from the group consisting of nitrogen and .dbd.CH--, G is selected from the group consisting of ##STR2## Z is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms or taken with Y forms a carbon-nitrogen or carbon-carbon bond, Z' is selected from the group consisting of hydrogen and halogen, Y is hydrogen, or taken with Z is a carbon-nitrogen or carbon-carbon bond or taken with X is .dbd.O and X is hydrogen or taken with Y is .dbd.O, R is selected from the group consisting of hydroxymethyl, formyl, tetrazol-5-yl, N-(tetrazol-5-yl) carbamoyl, aminomethyl and carbamoyl, R.sub.1 is selected from the group consisting of hydrogen, halogen and alkoxy of 1 to 5 carbon atoms and its non-toxic, pharmaceutically acceptable acid addition salts having antiallergic activity and their preparation.

  化合物的新颖结构式为##STR1## 其中A选自氮和.dbd.CH--的群组，G选自##STR2##的群组，Z选自1到5个碳原子的氢和烷基，或与Y一起形成碳氮或碳碳键，Z'选自氢和卤素的群组，Y为氢，或与Z一起形成碳氮或碳碳键，或与X一起为.dbd.O，X为氢，或与Y一起为.dbd.O，R选自羟甲基、甲酰基、四唑-5-基、N-(四唑-5-基)氨甲酰基、氨甲基和氨基甲酰基的群组，R.sub.1选自1到5个碳原子的卤素和烷氧基的群组，以及其无毒、药学上可接受的酸盐，具有抗过敏活性，并且可以制备这些化合物。
• BARNES, A. C.;KAY, D. P.;KENNEWELL, P. D.;PARKER, F. L.;ROWLANDS, D. A.
  作者：BARNES, A. C.、KAY, D. P.、KENNEWELL, P. D.、PARKER, F. L.、ROWLANDS, D. A.

  DOI：——

  日期：——
• AGER, IAN R.;BARNES, ALAN C.;DANSWAN, GEOFFREY W.;HAIRSINE, PETER W.;KAY,+, J. MED. CHEM., 31,(1988) N 6, 1098-1115
  作者：AGER, IAN R.、BARNES, ALAN C.、DANSWAN, GEOFFREY W.、HAIRSINE, PETER W.、KAY,+

  DOI：——

  日期：——